Is Pfizer’s established drugs’ decline in China a canary in a coalmine?
Amgen biosimilar debut boosted by UnitedHealthcare coverage
Novartis CEO says FDA process could’ve been handled better
Translating microbiome research into treatments
*scroll through previous pages at the bottom to get older news*
Want to stay updated on CP happenings? New features, new boards, CP wire articles, and more? Click here to subscribe
